1. Home
  2. CRBP vs SHMD Comparison

CRBP vs SHMD Comparison

Compare CRBP & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$7.88

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

HOLD

Current Price

$3.60

Market Cap

198.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
SHMD
Founded
2009
1864
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
198.2M
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
CRBP
SHMD
Price
$7.88
$3.60
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$45.50
N/A
AVG Volume (30 Days)
991.2K
762.4K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$6.33
$2.34
52 Week High
$20.56
$10.65

Technical Indicators

Market Signals
Indicator
CRBP
SHMD
Relative Strength Index (RSI) 34.64 44.30
Support Level $7.62 $3.01
Resistance Level $8.54 $3.65
Average True Range (ATR) 0.74 0.23
MACD -0.26 0.08
Stochastic Oscillator 26.45 53.73

Price Performance

Historical Comparison
CRBP
SHMD

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: